Table 2.
Sample source | Primary stimulus/ disease | Admistration route | Omic platform | Epigenetic change | Localization | Results | Ref. |
Infection | |||||||
Macrophage cultures from bone marrows mice | LPS | Intraperitoneal injection | ChIP-seq | Stable H3K4me1 (24h) Transient H3K27Ac (4h) |
Latent enhancer (unmarked in the basal state) |
LPS can activate 514 latent enhancers at 4 h and 1,002 at 24 h leading to a short-term transcriptional memory | [65] |
Peritoneal macrophages from mice | Candida albicans (β-glucans) |
Intraperitoneal injection | Chip-seq | Increase in H3K4me3 | Promoters | Protection against reinfection in a monocyte-dependent manner by enhancing dectin-1, C-type lectin receptors, pro-inflammatory cytokines such as TNF-α, IL-6 and IL-18, TLRs and TLR adaptor protein Myd88 | [66] |
Immune system diseases | |||||||
Mononuclear cells from mice |
arthritis | // | Chip-seq | Elevated levels of phosphorylated H3 |
Promoters | Upregulation of the AURKA and AURKB genes can lead to promotes proliferation of T lymphocytes. Treatment with the VX-680 attenuated inflammatory reactions and promoted the apoptosis of B cells |
[67] |
Mouse model of transient hyperglycemia and bovine aortic endothelial cells | Hyperglycemia | // | Chip-seq | Enhanced H3K4 and reduced H3K9 methylation | Promoters | High-glucose-mediated NFKB-p65 gene upregulation that is refractory to glycemic correction | [68] |
Abbreviations: AURKA: aurora kinases A; AURKB: aurora kinases B; VX-680; aurora kinase-specific inhibitor.